Nested Therapeutics Announces Oral Presentation of Preclinical Data for NST-628, a Novel, Fully Brain-Penetrant, Pan-RAF/MEK Molecular Glue, at the 2024 AACR Annual Meeting

Concurrent publication in the journal Cancer Discovery highlights NST-628's differentiated mechanism and preclinical activity across diverse KRAS-, NRAS-, and BRAF-driven tumors

Related Keywords

United States ,American ,Klaus Hoeflich ,Therapeutics Inc ,American Association For Cancer Research ,Linkedin ,Cancer Discovery ,American Association ,Cancer Research ,Fully Brain Penetrant ,Molecular Glue ,Driven Cancers ,Nested Therapeutics ,